



## Clinical trial results:

**Phase II study of the histone-deacetylase inhibitor GIVINOSTAT (ITF2357) in combination with hydroxyurea in patients with JAK2V617F positive Polycythemia Vera non-responder to hydroxyurea monotherapy.**

### Summary

EudraCT number	2009-010982-22
Trial protocol	IT
Global end of trial date	07 July 2011

### Results information

Result version number	v1
This version publication date	25 May 2019
First version publication date	25 May 2019

### Trial information

#### Trial identification

Sponsor protocol code	DSC/08/2357/38
-----------------------	----------------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00928707
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	Italfarmaco S.p.A.
Sponsor organisation address	Via dei Laboratori 54 , Milano, Italy, 20092
Public contact	Clinical Trial Transparency Manager, Italfarmaco S.p.A., Italfarmaco S.p.A., +39 02 66041503, info@italfarmaco.com
Scientific contact	Clinical Trial Transparency Manager, Italfarmaco S.p.A., Italfarmaco S.p.A., +39 02 66041503, info@italfarmaco.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

---

Analysis stage	Final
Date of interim/final analysis	07 July 2011
Is this the analysis of the primary completion data?	Yes
Primary completion date	07 July 2011
Global end of trial reached?	Yes
Global end of trial date	07 July 2011
Was the trial ended prematurely?	No

Notes:

---

**General information about the trial**

---

Main objective of the trial:

To evaluate the efficacy of GIVINOSTAT (ITF2357) in combination with hydroxyurea in patients with JAK2V617F positive Polycythemia Vera non-responders to the maximum tolerated dose of hydroxyurea monotherapy

Protection of trial subjects:

The study was conducted under the provisions of the Declaration of Helsinki and in accordance with the International Conference on Harmonisation (ICH) Consolidated Guideline on Good Clinical Practice (GCP).

Background therapy:

Hydroxyurea (HU) monotherapy was already in use before admission to the study and was continued at the maximum tolerated dose (MTD) throughout the study

Evidence for comparator: -

Actual start date of recruitment	09 July 2009
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

Country: Number of subjects enrolled	Italy: 45
Worldwide total number of subjects	45
EEA total number of subjects	45

Notes:

---

**Subjects enrolled per age group**

---

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	21
From 65 to 84 years	24

85 years and over	0
-------------------	---

## Subject disposition

### Recruitment

Recruitment details:

A total number of 45 patients were randomised to receive: 23 Givinostat 50 mg o.d. and 22 Givinostat 50 mg b.i.d. One subject in the o.d. group was discontinued due to ineligibility/protocol violation and did not receive the assigned treatment. Therefore, 22 patients in either group received treatment.

### Pre-assignment

Screening details:

Pre-enrolment screening tests and evaluations were used to determine eligibility of each candidate for study inclusion. All evaluations had to be performed within 2 weeks prior to starting treatment with Givinostat. If all eligibility criteria were met at screening visit, the treatment with Givinostat could start.

### Period 1

Period 1 title	Overall study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Blinding implementation details:

No blinding procedures are applicable as the study was open-label.

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Group A (50 mg od)

Arm description:

Group A: 50 mg o.d. of oral Givinostat in combination with the maximum tolerated dose of hydroxyurea monotherapy (already in use before admission to the study) were administered for 12 weeks. In case of no response at week 12, dose was increased to 50 mg b.i.d. in weeks 13-24.

Arm type	Experimental
Investigational medicinal product name	Givinostat
Investigational medicinal product code	
Other name	ITF2357
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

Givinostat 50 mg hard gelatine capsules for oral administration, in combination with hydroxyurea monotherapy at the maximum tolerated dose.

Investigational medicinal product name	Hydroxyurea
Investigational medicinal product code	
Other name	Onco Carbide, hydroxycarbamide
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

Hydroxyurea 500 mg capsules – already in use before admission to the study – at the maximum tolerated dose, in combination with Givinostat.

<b>Arm title</b>	Group B (50 mg bid)
------------------	---------------------

Arm description:

Group B: 50 mg b.i.d. of oral Givinostat in combination with the maximum tolerated dose of hydroxyurea monotherapy (already in use before admission to the study) were administered for 12 weeks. In case of no response at week 12, dose was increased to 50 mg t.i.d. in weeks 13-24.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Givinostat
Investigational medicinal product code	
Other name	ITF2357
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

Givinostat 50 mg hard gelatine capsules for oral administration, in combination with hydroxyurea monotherapy at the maximum tolerated dose.

Investigational medicinal product name	Hydroxyurea
Investigational medicinal product code	
Other name	Onco Carbide, hydroxycarbamide
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

Hydroxyurea 500 mg capsules – already in use before admission to the study – at the maximum tolerated dose, in combination with Givinostat.

<b>Number of subjects in period 1</b>	Group A (50 mg od)	Group B (50 mg bid)
Started	23	22
Completed	22	22
Not completed	1	0
ineligibility/protocol violation	1	-

## Baseline characteristics

### Reporting groups

Reporting group title	Group A (50 mg od)
-----------------------	--------------------

Reporting group description:

Group A: 50 mg o.d. of oral Givinostat in combination with the maximum tolerated dose of hydroxyurea monotherapy (already in use before admission to the study) were administered for 12 weeks. In case of no response at week 12, dose was increased to 50 mg b.i.d. in weeks 13-24.

Reporting group title	Group B (50 mg bid)
-----------------------	---------------------

Reporting group description:

Group B: 50 mg b.i.d. of oral Givinostat in combination with the maximum tolerated dose of hydroxyurea monotherapy (already in use before admission to the study) were administered for 12 weeks. In case of no response at week 12, dose was increased to 50 mg t.i.d. in weeks 13-24.

Reporting group values	Group A (50 mg od)	Group B (50 mg bid)	Total
Number of subjects	23	22	45
Age categorical Units: Subjects			
Adults (18-64 years)	10	11	21
From 65-84 years	13	11	24
Gender categorical Units: Subjects			
Female	9	7	16
Male	14	15	29

### Subject analysis sets

Subject analysis set title	Group A - Safety/ITT
----------------------------	----------------------

Subject analysis set type	Intention-to-treat
---------------------------	--------------------

Subject analysis set description:

Safety/Intention-to-treat (ITT) population, which included all randomized subjects who received at least one dose of study medication.

Subject analysis set title	Group B - Safety/ITT
----------------------------	----------------------

Subject analysis set type	Intention-to-treat
---------------------------	--------------------

Subject analysis set description:

Safety/Intention-to-treat (ITT) population, which included all randomized subjects who received at least one dose of study medication.

Reporting group values	Group A - Safety/ITT	Group B - Safety/ITT	
Number of subjects	22	22	
Age categorical Units: Subjects			
Adults (18-64 years)	9	11	
From 65-84 years	13	11	
Gender categorical Units: Subjects			
Female	9	7	
Male	13	15	

## End points

### End points reporting groups

Reporting group title	Group A (50 mg od)
Reporting group description: Group A: 50 mg o.d. of oral Givinostat in combination with the maximum tolerated dose of hydroxyurea monotherapy (already in use before admission to the study) were administered for 12 weeks. In case of no response at week 12, dose was increased to 50 mg b.i.d. in weeks 13-24.	
Reporting group title	Group B (50 mg bid)
Reporting group description: Group B: 50 mg b.i.d. of oral Givinostat in combination with the maximum tolerated dose of hydroxyurea monotherapy (already in use before admission to the study) were administered for 12 weeks. In case of no response at week 12, dose was increased to 50 mg t.i.d. in weeks 13-24.	
Subject analysis set title	Group A - Safety/ITT
Subject analysis set type	Intention-to-treat
Subject analysis set description: Safety/Intention-to-treat (ITT) population, which included all randomized subjects who received at least one dose of study medication.	
Subject analysis set title	Group B - Safety/ITT
Subject analysis set type	Intention-to-treat
Subject analysis set description: Safety/Intention-to-treat (ITT) population, which included all randomized subjects who received at least one dose of study medication.	

### Primary: Overall hematological response rate at week 12

End point title	Overall hematological response rate at week 12 <sup>[1]</sup>
End point description: The number and rate of patients with overall (complete or partial) response at week 12 were assessed. · Complete response: 1. HCT < 45% without phlebotomy, and 2. platelets ≤ 400 x10 <sup>9</sup> /L, and 3. WBC ≤ 10 x 10 <sup>9</sup> /L, and 4. no splenomegaly, and 5. no disease related systemic symptoms (microvascular disturbances, pruritus, headache); · Partial response: 1. HCT < 45% without phlebotomy, or 2. fulfilment of at least 3 of the other above mentioned criteria; · No response: any response that did not satisfy the criteria set for partial response.	
End point type	Primary
End point timeframe: At week 12	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis is available for this endpoint.

End point values	Group A - Safety/ITT	Group B - Safety/ITT		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	22	22		
Units: percentage of patients				
number (confidence interval 95%)				
Responder	54.5 (33.7 to 75.4)	50.0 (29.1 to 70.9)		
Non responder	45.5 (24.6 to 66.3)	50.0 (29.1 to 70.9)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Hematological response rate at week 24 by dose escalation after week 12

End point title	Hematological response rate at week 24 by dose escalation after week 12
-----------------	---

End point description:

Rate of haematological response after a 50 mg increase of the initial Givinostat dose in non-responder patients at the time when the primary endpoint was assessed (week 12).

· Complete response:

1. HCT < 45% without phlebotomy, and
2. platelets  $\leq 400 \times 10^9/L$ , and
3. WBC  $\leq 10 \times 10^9/L$ , and
4. no splenomegaly, and
5. no disease related systemic symptoms (microvascular disturbances, pruritus, headache);

· Partial response:

1. HCT < 45% without phlebotomy, or
2. fulfilment of at least 3 of the other above mentioned criteria;

· No response: any response that did not satisfy the criteria set for partial response.

End point type	Secondary
----------------	-----------

End point timeframe:

At week 24.

End point values	Group A - Safety/ITT	Group B - Safety/ITT		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	22	22		
Units: percentage of patients				
number (confidence interval 95%)				
Responder	63.6 (43.5 to 83.7)	40.9 (20.4 to 61.5)		
Non responder	36.4 (16.3 to 56.5)	59.1 (38.5 to 79.6)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Reduction of the JAK2V617F allele burden by quantitative RT-PCR

End point title	Reduction of the JAK2V617F allele burden by quantitative RT-PCR
-----------------	---



End point description:

Quantitative RT-PCR for JAK2V617F mutational status on peripheral blood (PB) granulocyte and haematopoietic colonies (with and without HGFs).

End point type	Secondary
----------------	-----------

End point timeframe:

At weeks 12, 24, at "drop out visit" and at "End of Study" (EOS). EOS stays for 7 days after last drug intake if patient is withdrawn from the study before week 24.

End point values	Group A - Safety/ITT	Group B - Safety/ITT		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	22	21		
Units: percentage				
arithmetic mean (standard deviation)				
Week 12	-2.6 (± 8.2)	0.0 (± 6.0)		
Week 24	-3.8 (± 11.5)	4.6 (± 5.7)		
Drop-out	-4.0 (± 000)	-9.5 (± 20.5)		
EOS	-3.8 (± 11.1)	3.0 (± 8.6)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Reduction of the fraction of JAK2V617F positive clonogenic progenitor

End point title	Reduction of the fraction of JAK2V617F positive clonogenic progenitor
-----------------	---

End point description:

JAK2V617F genotyping and quantification were performed on gradient-separated mononuclear cells during the pre-treatment evaluations, halfway through the study (12th weeks) and at the end of the study period (24th weeks). Only data at baseline are reported. No significant reduction of the mean fraction of JAK2V617F positive clonogenic progenitor from baseline to both week 12 and week 24 in both groups was observed.

End point type	Secondary
----------------	-----------

End point timeframe:

At week 12 and at week 24

End point values	Group A - Safety/ITT	Group B - Safety/ITT		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	22	22		
Units: number of subject				
Heterozygous	6	5		
Homozygous	16	16		
Not done	0	1		

## **Statistical analyses**

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

AE were recorded at weeks 1 ,3, 6, 9, 12, 16, 20 or end of treatment visit (week 24 or 7 days after last drug intake)

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	13.0
--------------------	------

### Reporting groups

Reporting group title	Group A - 50 mg o.d. - Safety/ITT
-----------------------	-----------------------------------

Reporting group description:

Safety/Intention-to-treat (ITT) population included all randomized subjects who received at least one dose of study medication.

Reporting group title	Group B - 50 mg bid - Safety/ITT
-----------------------	----------------------------------

Reporting group description:

Safety/Intention-to-treat (ITT) population included all randomized subjects who received at least one dose of study medication.

Serious adverse events	Group A - 50 mg o.d. - Safety/ITT	Group B - 50 mg bid - Safety/ITT	
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 22 (9.09%)	1 / 22 (4.55%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Surgical and medical procedures			
Appendicectomy			
subjects affected / exposed	1 / 22 (4.55%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Social circumstances			
Pregnancy of partner			
subjects affected / exposed	0 / 22 (0.00%)	1 / 22 (4.55%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Embolism			
subjects affected / exposed	1 / 22 (4.55%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 4 %

<b>Non-serious adverse events</b>	Group A - 50 mg o.d. - Safety/ITT	Group B - 50 mg bid - Safety/ITT	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	21 / 22 (95.45%)	21 / 22 (95.45%)	
Vascular disorders			
Haematoma			
subjects affected / exposed	1 / 22 (4.55%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Hypertension			
subjects affected / exposed	0 / 22 (0.00%)	2 / 22 (9.09%)	
occurrences (all)	0	2	
Phlebitis			
subjects affected / exposed	0 / 22 (0.00%)	1 / 22 (4.55%)	
occurrences (all)	0	1	
Thrombophlebitis superficial			
subjects affected / exposed	1 / 22 (4.55%)	0 / 22 (0.00%)	
occurrences (all)	2	0	
Surgical and medical procedures			
Curetting of chalazion			
subjects affected / exposed	1 / 22 (4.55%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	2 / 22 (9.09%)	2 / 22 (9.09%)	
occurrences (all)	2	2	
Fatigue			
subjects affected / exposed	2 / 22 (9.09%)	1 / 22 (4.55%)	
occurrences (all)	2	1	
Oedema			
subjects affected / exposed	0 / 22 (0.00%)	1 / 22 (4.55%)	
occurrences (all)	0	1	

Pyrexia subjects affected / exposed occurrences (all)	2 / 22 (9.09%) 3	1 / 22 (4.55%) 1	
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)  Dyspnoea subjects affected / exposed occurrences (all)  Epistaxis subjects affected / exposed occurrences (all)  Oropharyngeal pain subjects affected / exposed occurrences (all)	1 / 22 (4.55%) 1  1 / 22 (4.55%) 1  1 / 22 (4.55%) 1  0 / 22 (0.00%) 0	1 / 22 (4.55%) 1  0 / 22 (0.00%) 0  1 / 22 (4.55%) 1  1 / 22 (4.55%) 1	
Psychiatric disorders Anxiety subjects affected / exposed occurrences (all)  Panic attack subjects affected / exposed occurrences (all)	0 / 22 (0.00%) 0  0 / 22 (0.00%) 0	1 / 22 (4.55%) 1  1 / 22 (4.55%) 1	
Investigations Aspartate aminotransferase increased subjects affected / exposed occurrences (all)  Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)  BBlood creatine phosphokinase increased subjects affected / exposed occurrences (all)  Blood creatinine increased	1 / 22 (4.55%) 1  1 / 22 (4.55%) 2  1 / 22 (4.55%) 1  1 / 22 (4.55%) 1	0 / 22 (0.00%) 0  1 / 22 (4.55%) 1  0 / 22 (0.00%) 0	

subjects affected / exposed occurrences (all)	3 / 22 (13.64%) 3	2 / 22 (9.09%) 6	
Blood magnesium increased subjects affected / exposed occurrences (all)	2 / 22 (9.09%) 2	0 / 22 (0.00%) 0	
Blood triglycerides increased subjects affected / exposed occurrences (all)	0 / 22 (0.00%) 0	1 / 22 (4.55%) 4	
Blood urea increased subjects affected / exposed occurrences (all)	1 / 22 (4.55%) 1	0 / 22 (0.00%) 0	
Electrocardiogram QT prolonged subjects affected / exposed occurrences (all)	0 / 22 (0.00%) 0	2 / 22 (9.09%) 2	
Platelet count increased subjects affected / exposed occurrences (all)	1 / 22 (4.55%) 1	0 / 22 (0.00%) 0	
White blood cell count increased subjects affected / exposed occurrences (all)	1 / 22 (4.55%) 1	0 / 22 (0.00%) 0	
Injury, poisoning and procedural complications Injury subjects affected / exposed occurrences (all)	1 / 22 (4.55%) 1	0 / 22 (0.00%) 0	
Cardiac disorders Arrhythmia subjects affected / exposed occurrences (all)	1 / 22 (4.55%) 1	0 / 22 (0.00%) 0	
Atrial fibrillation subjects affected / exposed occurrences (all)	0 / 22 (0.00%) 0	1 / 22 (4.55%) 1	
Tachycardia subjects affected / exposed occurrences (all)	1 / 22 (4.55%) 1	0 / 22 (0.00%) 0	
Nervous system disorders			

Dizziness			
subjects affected / exposed	2 / 22 (9.09%)	0 / 22 (0.00%)	
occurrences (all)	2	0	
Headache			
subjects affected / exposed	2 / 22 (9.09%)	1 / 22 (4.55%)	
occurrences (all)	2	1	
Paraesthesia			
subjects affected / exposed	1 / 22 (4.55%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 22 (4.55%)	2 / 22 (9.09%)	
occurrences (all)	1	3	
Leukopenia			
subjects affected / exposed	0 / 22 (0.00%)	2 / 22 (9.09%)	
occurrences (all)	0	3	
Lymphadenitis			
subjects affected / exposed	1 / 22 (4.55%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Lymphopenia			
subjects affected / exposed	0 / 22 (0.00%)	1 / 22 (4.55%)	
occurrences (all)	0	3	
Thrombocytopenia			
subjects affected / exposed	5 / 22 (22.73%)	7 / 22 (31.82%)	
occurrences (all)	5	8	
Thrombocytosis			
subjects affected / exposed	0 / 22 (0.00%)	1 / 22 (4.55%)	
occurrences (all)	0	1	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	3 / 22 (13.64%)	1 / 22 (4.55%)	
occurrences (all)	3	1	
Abdominal pain upper			
subjects affected / exposed	2 / 22 (9.09%)	3 / 22 (13.64%)	
occurrences (all)	2	3	
Constipation			

subjects affected / exposed	2 / 22 (9.09%)	1 / 22 (4.55%)	
occurrences (all)	2	1	
Diarrhoea			
subjects affected / exposed	10 / 22 (45.45%)	7 / 22 (31.82%)	
occurrences (all)	12	10	
Dyspepsia			
subjects affected / exposed	0 / 22 (0.00%)	2 / 22 (9.09%)	
occurrences (all)	0	2	
Gastritis			
subjects affected / exposed	1 / 22 (4.55%)	1 / 22 (4.55%)	
occurrences (all)	1	1	
Haematochezia			
subjects affected / exposed	1 / 22 (4.55%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 22 (0.00%)	1 / 22 (4.55%)	
occurrences (all)	0	1	
Nausea			
subjects affected / exposed	3 / 22 (13.64%)	0 / 22 (0.00%)	
occurrences (all)	3	0	
Stomatitis			
subjects affected / exposed	2 / 22 (9.09%)	1 / 22 (4.55%)	
occurrences (all)	3	1	
Tongue haemorrhage			
subjects affected / exposed	0 / 22 (0.00%)	1 / 22 (4.55%)	
occurrences (all)	0	1	
Vomiting			
subjects affected / exposed	1 / 22 (4.55%)	1 / 22 (4.55%)	
occurrences (all)	1	1	
Skin and subcutaneous tissue disorders			
Actinic keratosis			
subjects affected / exposed	1 / 22 (4.55%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Eczema			
subjects affected / exposed	0 / 22 (0.00%)	1 / 22 (4.55%)	
occurrences (all)	0	1	



Renal and urinary disorders			
Dysuria			
subjects affected / exposed	1 / 22 (4.55%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Renal colic			
subjects affected / exposed	0 / 22 (0.00%)	1 / 22 (4.55%)	
occurrences (all)	0	1	
Endocrine disorders			
Goitre			
subjects affected / exposed	0 / 22 (0.00%)	1 / 22 (4.55%)	
occurrences (all)	0	1	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 22 (4.55%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Back pain			
subjects affected / exposed	0 / 22 (0.00%)	2 / 22 (9.09%)	
occurrences (all)	0	2	
Myalgia			
subjects affected / exposed	1 / 22 (4.55%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Infections and infestations			
Genitourinary tract infection			
subjects affected / exposed	0 / 22 (0.00%)	1 / 22 (4.55%)	
occurrences (all)	0	2	
Influenza			
subjects affected / exposed	3 / 22 (13.64%)	1 / 22 (4.55%)	
occurrences (all)	3	1	
Pharyngitis			
subjects affected / exposed	1 / 22 (4.55%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Rhinitis			
subjects affected / exposed	0 / 22 (0.00%)	1 / 22 (4.55%)	
occurrences (all)	0	1	
Tooth abscess			

subjects affected / exposed occurrences (all)	0 / 22 (0.00%) 0	1 / 22 (4.55%) 1	
Urogenital infection fungal subjects affected / exposed occurrences (all)	0 / 22 (0.00%) 0	1 / 22 (4.55%) 1	
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	1 / 22 (4.55%) 1	1 / 22 (4.55%) 1	
Hyperkalaemia subjects affected / exposed occurrences (all)	2 / 22 (9.09%) 3	1 / 22 (4.55%) 1	
Hyperuricaemia subjects affected / exposed occurrences (all)	2 / 22 (9.09%) 3	1 / 22 (4.55%) 2	
Hypokalaemia subjects affected / exposed occurrences (all)	0 / 22 (0.00%) 0	1 / 22 (4.55%) 1	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
15 September 2009	The key features of the present amendment are: a) the variation of one exclusion criteria, b) the collection of a whole blood sample both at Baseline and at the middle of the study (at Week 12), c) the increase of study Centers number.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

No limitations and caveats are applicable to this summary of results.
---

Notes: